Updated Trends,Proteasomes are the major nonlysosomal protein degradation machinery

The intricate cellular machinery responsible for protein degradation, known as the proteasome, is a critical player in maintaining cellular homeostasis. When this system malfunctions, it can lead to a cascade of detrimental effects, contributing to various diseases. This has spurred significant interest in developing strategies to target the proteasome for therapeutic intervention. Among these, proteasome targeting peptide approaches are emerging as a powerful and versatile modality.

At its core, the proteasome is an essential protein complex responsible for the degradation of proteins by proteolysis, a chemical reaction that breaks peptide bonds. This process is fundamental for cellular health, clearing misfolded or damaged proteins and regulating the abundance of key regulatory proteins. The 26S proteasome, a larger complex, is particularly known for its role in degrading ubiquitinated proteins, while the 20S proteasome can also target IDPs or oxidized proteins.

The development of strategies to manipulate proteasome function has led to innovative therapeutic concepts. One such advancement is the PROteolysis TArgeting Chimera (PROTAC), a new type of treatment that can induce the dynamic degradation of intracellular or nuclear proteins. PROTACs are bifunctional molecules, typically composed of a target protein binding peptide (TBP), a linker peptide (LP), and a ligand that recruits an E3 ligase. By bringing a target protein into close proximity with an E3 ligase, PROTACs facilitate the ubiquitination of the target, marking it for degradation by the proteasome system. This mechanism allows for the selective elimination of disease-causing proteins.

Beyond traditional PROTACs, the field is exploring peptide PROTAC modalities, which leverage peptide sequences to achieve targeted protein degradation. These peptide-based chimeric strategies are advancing peptide-driven degradation technologies, including those that harness the ubiquitin-proteasome system. Research is also investigating peptide splicing by the proteasome, where the proteasome is the major protease responsible for the production of antigenic peptides recognized by CD8+ cytolytic T cells (CTLs). This highlights the proteasome's crucial role in immune surveillance.

Furthermore, extended peptide-based inhibitors are being developed to efficiently target the proteasome and reveal overlapping specificities of its catalytic beta-subunits. These inhibitors can modulate proteasome activity, offering therapeutic avenues. For instance, certain peptides can activate the 20S proteasome by gate opening, such as proteasome-activating peptide 1 (PAP1), which increases chymotrypsin-like proteasomal catalytic activity. Conversely, peptide and peptide-like modulators of 20S proteasome activity are being investigated as novel cytotoxic and antiproliferative agents, with a particular focus on the chymotrypsin-like activity.

The generation of antigenic peptides is a key function of the proteasome. Antigenic peptides are generated from the proteasomal degradation of endogenously synthesized proteins or exogenous proteins acquired by host cells. These peptides, typically 8-10 amino acids in length, are then loaded onto MHC Class I proteins. This process is fundamental for the immune system's ability to recognize and eliminate infected or cancerous cells. Indeed, proteasomes are the major nonlysosomal protein degradation machinery in eukaryotic cells and are largely responsible for the processing of antigens for presentation.

Recent research is also exploring novel strategies such as targeted degradation via direct 26S proteasome recruitment. This approach bypasses the need for ubiquitination in some cases, offering an alternative way to direct substrates to the proteasome for degradation. Moreover, the discovery of proteasomes in the constitutive and bacterial-induced generation of defense peptides that impede bacterial growth further underscores the multifaceted roles of this cellular machine.

The therapeutic potential of proteasome targeting peptide strategies extends to various disease areas. For example, enhanced proteasome activity is believed to be beneficial for cell function, particularly relevant to aging. In cancer therapy, peptide-based PROTACs are being designed to degrade specific oncogenic proteins, such as p300. The development of cell-penetrating peptide conjugated proteasome inhibitors has also shown promise, with some exhibiting anticancer and antifungal activities.

The field of targeted protein degradation (TPD) is rapidly advancing, offering exciting new modalities for inducing target protein destruction in cells by harnessing cellular machinery. PROTACs hijack the proteasome system, while other strategies like LYTACs exploit different cellular mechanisms. The ability to precisely target and degrade specific proteins using proteasome targeting peptide approaches represents a significant leap forward in drug development, holding the promise of more effective and selective treatments for a wide range of diseases. The ongoing exploration of peptide PROTAC and other peptide-based strategies underscores the versatility and power of **pe